Idera Pharmaceuticals to Present at the Nucleic Acid Summit 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Idera Pharmaceuticals, Inc. IDRA, a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today announced that Walter Strapps, Ph.D., Executive Director of RNA Therapeutics, will present at the Nucleic Acid Summit 2014 in San Diego, California on Thursday, June 19, 2014 at 4:15 p.m. PDT. The title of Dr. Strapps' presentation is "Gene Silencing Oligos: The Next Generation in Gene Silencing."

A copy of the presentation will be available on the Idera website located at: http://www.iderapharma.com/our-science/key-presentations-and-publications.

About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.